According to filings with the U.S. Securities and Exchange Commission, Alloy Therapeutics is raised $40 Million in new Series E funding. The federal securities law requires the notice to be filed by companies that have sold securities without registration under the Securities Act of 1933 in an offering made under Rule 504 or 506 of Regulation D or Section 4(a)(5) of the Securities Act. A company must file this notice within 15 days after the first sale of securities in the offering. For this purpose, the date of first sale is the date on which the first investor is irrevocably contractually committed to invest. Each issuer of securities that sells its securities in reliance on an exemption provided in Regulation D or Section 4(a)(5) of the Securities Act of 1933 must file this notice containing the information requested with the U.S. Securities and Exchange Commission (SEC) and with the state(s) requiring it. If more than one issuer has sold its securities in the same transaction, all issuers should be identified in this filing with the SEC.

About Alloy Therapeutics
Alloy Therapeutics is a biotechnology ecosystem company powering the future of drug discovery and development with AI-powered platforms and scientific expertise. Through a collaborative partnership approach, Alloy provides access to proprietary technologies, services, and company-creation capabilities that are foundational to discovering and developing therapeutics across multiple modalities: antibodies, bispecifics, TCRms, genetic medicines, cell therapies, and drug delivery. Alloy integrates AI/ML into its discovery and development infrastructure, combining proprietary models, real-world data, and human expertise to help partners advance therapeutic programs. At Alloy, we are redefining biologics development by reducing the time and cost to advance programs from discovery to human data.

To learn more, visit https://alloytx.com/
Linkedin Page: https://www.linkedin.com/company/alloy-therapeutics-inc/

Contact:
Errik Anderson, Chief Executive Officer
https://www.linkedin.com/in/errikanderson/

SOURCE: http://www.intelligence360.io
Copyright (c) 2026 SI360 Inc. All rights reserved.